secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vir Biotechnology, Inc. (VIR)
CIK:        0001706431
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0000950170-22-021846
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vir Biotech Q3 revenue $374.6M; BARDA contract up to $1B; Phase 2 data in 2023
------------------------------------------------------------------------------

- Q3 2022 revenue $374.6M (vs $103.6M YoY); net income $175.3M ($1.32 basic EPS) vs $110.4M ($0.85) in Q3 2021.
- BARDA awards contract for pandemic preparedness: initial ~$55M, potential up to $1B.
- GSK opted-in to collaborate on RSV antibodies; profit-sharing from GSK $291.2M in Q3.
- Phase 2 trials for HBV, HDV (SOLSTICE), influenza A (PENINSULA); initial data expected in 2023.
- Strong balance sheet: ~$2.7B cash, investments, and profit-share payments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1706431/000095017022021846/0000950170-22-021846-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1706431/000095017022021846/vir-20221103.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-021846

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer